- Country: Ukraine
- Summary: Dk 021:2015 33600000-6 Pharmaceutical Products (Amikacin, Solution for Injection, 250 Mg/Ml 2 Ml; Amikacin, Solution for Injection, 250 Mg/Ml 4 Ml (1000 Mg); Vancomycin Lyophilisate/Powder for Solution for Other...
- UAT Ref No: 133358286
- Deadline: 12 Jan 2026
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: UAH 10172785.41
- Notice Type: Tender
- Document Ref. No.: UA-2026-01-07-007282-a
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- DK 021:2015 33600000-6 Pharmaceutical products (Amikacin, solution for injection, 250 mg/ml 2 ml; Amikacin, solution for injection, 250 mg/ml 4 ml (1000 mg); Vancomycin lyophilisate/powder for solution for infusion 1000 mg each; Amoxicillin and clavulanate acid, powder for injections/infusions 1.2 g; Amoxicillin/clavulanic acid film-coated tablets, 875 mg/125 mg; Azithromycin, lyophilisate/powder for solution, 500 mg each; Imipenem/Celastatin 500mg/500mg powder for solution for infusions; Piperacillin/tazobactam, powder (lyophilisate) for solution, 4 g/0.5 g each; Meropenem, powder for injections/infusions, 1 g each; Cefotaxime, powder for injections of 1 g; Ceftazidime, powder for injection 1.0 g; Cefepime, powder for injection 1.0; ΠΡΠ΅ΠΏΠ°ΡΠ°Ρ Π·Π°Π»ΡΠ·Π°, ΡΠΎΠ·ΡΠΈΠ½ for injections and infusions, 20 mg/ml, 5 ml each; Levofloxacin solution for infusions, 5 mg/ml, 100 ml; Linezolid solution for infusions, 2 mg/ml in 300 ml; Thiopental, powder/lyophilisate, 1 g each; Enoxaparin sodium, solution for injection, 10,000 anti-Xa IU/ml, 0.8 ml each; Ibuprofen solution for infusions 4 mg/ml per 100 ml; Paracetamol solution for infusions 10 mg/ml 100 ml; Omeprazole 40 mg bottle; Omeprazole 40 mg capsules; Omeprazole 20 mg capsules; Colistin powder for solution for injection or infusion 2,000,000 IU; Vancomycin lyophilisate/powder for solution for infusions of 500 mg; Ibuprofen solution for infusions 100 mg/ml in 4 ml; Moxifloxacin solution for infusions, 400 mg/250 ml, 250 ml each; Linezolid film-coated tablets, 600 mg each) Type of purchase: goods Classifier and its relevant code: DC 021:2015: 33600000-6 β Pharmaceutical products Meropenem, powder for injections/infusions, 1 g each; Iron preparation, solution for injections and infusions, 20 mg/ml, 5 ml each; Ibuprofen solution for infusions 4 mg/ml 100 ml M01AE01, Ibuprofen, Solution for infusion, 4 mg/ml, Container, Vial, 100 milliliters; Ibuprofen: Classification according to ATC: M01AE01, Classification according to INN: Ibuprofen,...
- Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINDk 021:2015 33600000-6 Pharmaceutical Products (Amikacin, Solution for Injection, 250 Mg/Ml 2 Ml; Amikacin, Solution for Injection, 250 Mg/Ml 4 Ml (1000 Mg); Vancomycin Lyophilisate/Powder for Solution for Other... - Ukraine Tender
The MUNICIPAL ENTERPRISE "VOLODYMYRS TERRITORIAL MEDICAL ASSOCIATION" OF VOLODMYRS CITY COUNCIL, a Government sector organization in Ukraine, has announced a new tender for Dk 021:2015 33600000-6 Pharmaceutical Products (Amikacin, Solution for Injection, 250 Mg/Ml 2 Ml; Amikacin, Solution for Injection, 250 Mg/Ml 4 Ml (1000 Mg); Vancomycin Lyophilisate/Powder for Solution for Other.... This tender is published on UkraineTenders under UAT Ref No: 133358286 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2026-01-12.
The estimated tender value is UAH 10172785.41, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
